We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Experts: Amarin Deal Forces FDA’s Hand on Off-label Promotion
Experts: Amarin Deal Forces FDA’s Hand on Off-label Promotion
Say “sayonara” to the status quo of pharmaceutical promotional review. That’s the consensus of industry experts weighing the implications of the FDA’s decision Tuesday to settle Amarin’s First Amendment lawsuit.